Three products. One architecture.

From first diagnostic to ongoing execution - a complete infrastructure for companies that take people architecture seriously.

NexStep Emerge Pre-Seed to Series B

For founders building fast enough that the architecture beneath them deserves scrutiny.

+

What gets a company to 20 people rarely gets it to 200. The hiring instincts, the informal decision-making, the culture that ran on proximity and founder energy - these are features of the early stage. At the next one, they become friction.

NexStep Emerge is built for companies on that trajectory. Pre-Seed through Series B - the stages where the business is moving fast, the team is growing, and the people architecture is either quietly keeping pace or quietly falling behind. The output is board-presentable from day one. The process asks 30 minutes of each participant. The diagnostic completes within days.

The evidence base.

You know the business is moving. What you don't yet know is whether the architecture beneath it is moving with it. Diagnose tells you precisely where the gaps are - and how deep.

  • Risk report and Diagnostic Core, board-presentable from the moment they generate
  • 8 parameters, 76 sub-parameters, across four organisational vantage points
  • 43 context inputs calibrated to your operating reality, not a generic benchmark
  • Delivered within days, not weeks

The direction.

Diagnose tells you where the gaps are. Strategize tells you what to do about them - sequenced, prioritised, and built for the board conversation you are about to have.

  • Everything in Diagnose
  • Strategic Roadmap: initiatives ranked by urgency, impact, and feasibility
  • 90-day action plan with ownership prompts built in
  • Board narrative layer: translates findings into investor-ready language

The conviction to act.

Strategize gives you the direction. Augment gives you the qualitative depth that explains what the data shows - and gives you the conviction to act on it.

  • Everything in Strategize
  • Up to ten confidential interviews across hierarchical levels, functions, and tenures
  • Findings woven directly into your Risk Report and Strategic Roadmap
  • Stakeholder-level validation that structured data alone cannot deliver
NexStep Scale Series C to Pre-IPO

For organisations who want to demonstrate operating readiness to their board and investors.

+

As you move beyond Series B, the product is proven, the capital is committed. What your stakeholders and capital markets now need is evidence that the operating architecture beneath it can carry the weight of what comes next.

NexStep Scale is built for organisations at that inflection. Series C through Pre-IPO - the stages where people architecture complexity has outpaced the instruments used to manage it, and where the cost of that gap is measured in board conversations, not just execution friction. Your board, your investors, and your next capital event demand institutional-grade people architecture. NexStep Scale is how you prove it.

The institutional evidence base.

At Series C and beyond, the roadmap is not a list of actions. It is a structural commitment with ownership, sequencing, and a line of sight to capital events.

  • Risk report and Diagnostic Core, board-presentable from the moment they generate
  • 8 parameters, 76 sub-parameters, across four organisational vantage points
  • 43 context inputs calibrated to your operating reality, not a generic benchmark
  • Benchmarked against institutional standards for organisations at your stage
  • Delivered within days, not weeks

The architecture for what comes next.

Your board does not want a list of HR initiatives. They want a structural plan that maps people architecture to capital deployment. Strategize delivers exactly that.

  • Everything in Diagnose
  • Strategic Roadmap built for board-level presentation and investor scrutiny
  • Initiative sequencing aligned to capital event timelines
  • 90-day action plan with ownership and accountability built in
  • Board narrative layer: translates findings into the language your investors already speak

The conviction to act.

Strategize gives you the direction. Augment gives you the qualitative depth that explains what the data shows - and gives you the conviction to act on it.

  • Everything in Strategize
  • Up to ten confidential interviews across hierarchical levels, functions, and tenures
  • Findings woven directly into your Risk Report and Strategic Roadmap
  • Stakeholder-level validation that structured data alone cannot deliver
NexStep Anchor From roadmap to execution.

For leadership teams who have the roadmap and need the infrastructure to execute it.

Launching 1 May 2026
+

Knowing what needs to change and having the infrastructure to change it are two different things. The clearest roadmap in the world requires ownership, accountability, and a way to show the board that what was committed to is actually happening.

NexStep Anchor converts your roadmap into a live execution layer - every initiative owned, every milestone tracked, every outcome presented in the language your board already speaks. Progress is measured in structural change, not tasks completed.

Eligibility

Anchor is available to sponsors who have completed a NexStep Project at Strategize or Augment tier. Your initiatives from that engagement become the starting state - no manual setup required.

The Initiative Lifecycle

Define

The initiative is scoped and shaped by the people who will lead it. Everyone enters with genuine ownership, not assigned compliance.

Design

The intellectual work. Frameworks built, approaches decided, solutions designed before a single resource is committed.

Validate

Alignment secured. The design is pressure-tested with the right stakeholders before execution begins.

Execute

The work happens. Activities tracked, milestones reached, progress visible to everyone who needs to see it.

Measure

Impact assessed against the success criteria set at the start - not retrospectively defined.

Embed

Outcomes institutionalised. The work becomes the way the organisation operates.